SYSTEM UPDATE: We will be performing system maintenace Saturday September 26 at 9pm to midnight Pacific Time

Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26458771  

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.

Melinda E Varney | Madeline Niederkorn | Hiroyasu Konno | Takayuki Matsumura | Jin Gohda | Nobuaki Yoshida | Taishin Akiyama | Susanne Christie | Jing Fang | David Miller | Andres Jerez | Aly Karsan | Jaroslaw P Maciejewski | Ruhikanta A Meetei | Jun-ichiro Inoue | Daniel T Starczynowski
The Journal of experimental medicine | 2015

TRAF-interacting protein with forkhead-associated domain B (TIFAB) is a haploinsufficient gene in del(5q) myelodysplastic syndrome (MDS). Deletion of Tifab results in progressive bone marrow (BM) and blood defects, including skewed hematopoietic stem/progenitor cell (HSPC) proportions and altered myeloid differentiation. A subset of mice transplanted with Tifab knockout (KO) HSPCs develop a BM failure with neutrophil dysplasia and cytopenia. In competitive transplants, Tifab KO HSPCs are out-competed by wild-type (WT) cells, suggesting a cell-intrinsic defect. Gene expression analysis of Tifab KO HSPCs identified dysregulation of immune-related signatures, and hypersensitivity to TLR4 stimulation. TIFAB forms a complex with TRAF6, a mediator of immune signaling, and reduces TRAF6 protein stability by a lysosome-dependent mechanism. In contrast, TIFAB loss increases TRAF6 protein and the dynamic range of TLR4 signaling, contributing to ineffective hematopoiesis. Moreover, combined deletion of TIFAB and miR-146a, two genes associated with del(5q) MDS/AML, results in a cooperative increase in TRAF6 expression and hematopoietic dysfunction. Re-expression of TIFAB in del(5q) MDS/AML cells results in attenuated TLR4 signaling and reduced viability. These findings underscore the importance of efficient regulation of innate immune/TRAF6 signaling within HSPCs by TIFAB, and its cooperation with miR-146a as it relates to the pathogenesis of hematopoietic malignancies, such as del(5q) MDS/AML.

Pubmed ID: 26458771

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK102759
  • Agency: NIEHS NIH HHS, United States
    Id: T32 ES007250
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL114582
  • Agency: Canadian Institutes of Health Research, Canada
    Id: MOP 133455
  • Agency: NCI NIH HHS, United States
    Id: T32 CA117846
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL111103
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL111103
  • Agency: NIEHS NIH HHS, United States
    Id: 5T32ES007250-25

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


GeneChip Operating Software (tool)

RRID:SCR_003408

Affymetrix has recently released a new software for the acquisition, management, and analysis of gene expression data. The new GeneChip Operating Software (GCOS) platform enables researchers to perform gene expression, SNP mapping and resequencing analysis with integrated data management and scalable client server configurations. * Compatible with additional Affymetrix analysis software such as Data Mining Tool (DMT) and GeneChip DNA Analysis Software (GDAS) * Supports Gene Expression, Resequencing and Genotyping Applications * Baseline Comparison Analysis Input: Affymetrix .DAT file Output: Affymetrix files (.CEL, .CHP, .RPT, .EXP, .TXT) Availability: The Core Facility has a copy of GCOS, as well as an older version of the Affymetrix software, Microarray Suite (MAS), available for use upon request.

View all literature mentions

MOgene (tool)

RRID:SCR_012433

Core provides services to its partners in deploying genomic capabilities to bring critical solutions to both agriculture and industrial biotech operations. Core facility also provides assistance to research, biotech/pharma and government facilities. In addition to being an Agilent Certified Service Provider MOgene is also a CLIA certified genomics service facility offering one stop service and solution from Tissue/Cells to Analysis. Core offers RNA/DNA isolation, Microarrays, NextGen sequencing, Real time PCR and bioinformatics services.

View all literature mentions

THP-1 (tool)

RRID:CVCL_0006

Cell line THP-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

HL-60 (tool)

RRID:CVCL_0002

Cell line HL-60 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

HL-60 (tool)

RRID:CVCL_0002

Cell line HL-60 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Keck MirKO ES cell line Mir146a (tool)

RRID:MMRRC_036857-UCD

Mus musculus with name Keck MirKO ES cell line Mir146a from MMRRC.

View all literature mentions

Keck MirKO ES cell line Mir146a (tool)

RRID:MMRRC_036857-UCD

Mus musculus with name Keck MirKO ES cell line Mir146a from MMRRC.

View all literature mentions

Keck MirKO ES cell line Mir146a (tool)

RRID:MMRRC_036857-UCD

Mus musculus with name Keck MirKO ES cell line Mir146a from MMRRC.

View all literature mentions